Available Technology

Microfluidized Mycobacterium Avium Fragments as an Adjuvant And Carrier For Mucosal Vaccine Delivery

A vaccine adjuvant and immunogenic composition may be described herein. The vaccine adjuvant may comprise cell wall fragments of the genus Mycobacterium, and more particularly, of M avium. The immunogenic composition may include the vaccine adjuvant conjugated to an antigen.


  • Cell wall fragments of M. avium (herein also referred to as MAF) may be conjugated to an antigen targeting Gonadotropin releasing hormone (GnRH).
  • The MAF-antigen conjugate may be delivered for the purposes of treatment through one of several methods, including intramuscular injection, naso-pharyngeal, or oral.
Patent Number: 
Patent Issue Date: 
October 8, 2019
Lab Representatives
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin